Detalhe da pesquisa
1.
Durable remission of thrombotic thrombocytopenic purpura in the setting of pembrolizumab therapy.
Transfusion
; 63(6): 1241-1245, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37096845
2.
Safety and efficacy of pomalidomide, dexamethasone and pegylated liposomal doxorubicin for patients with relapsed or refractory multiple myeloma.
Br J Haematol
; 180(1): 60-70, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29164606
3.
Outcomes of multiple myeloma patients receiving bortezomib, lenalidomide, and carfilzomib.
Ann Hematol
; 96(3): 449-459, 2017 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-27933373
4.
Improved clinical outcomes for multiple myeloma patients treated at a single specialty clinic.
Ann Hematol
; 96(3): 441-448, 2017 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-27913860
5.
Safety of BTZ retreatment for patients with low-grade peripheral neuropathy during the initial treatment.
Support Care Cancer
; 25(10): 3217-3224, 2017 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28455546
6.
A phase 3 trial of armodafinil for the treatment of cancer-related fatigue for patients with multiple myeloma.
Support Care Cancer
; 23(6): 1503-12, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-25370889
7.
A phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma.
Ann Hematol
; 93(1): 89-98, 2014 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-24135804
8.
Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.
Br J Haematol
; 160(3): 321-30, 2013 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-23150919
9.
A modified regimen of pegylated liposomal doxorubicin, bortezomib and dexamethasone (DVD) is effective and well tolerated for previously untreated multiple myeloma patients.
Br J Haematol
; 155(5): 580-7, 2011 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-21950583
10.
Prognostic factors and jaw and renal complications among multiple myeloma patients treated with zoledronic acid.
Am J Hematol
; 86(1): 25-30, 2011 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-21120861
11.
A phase I study of samarium lexidronam/bortezomib combination therapy for the treatment of relapsed or refractory multiple myeloma.
Clin Cancer Res
; 15(3): 1069-75, 2009 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-19188182
12.
Evaluation of long-term cardiovascular effects.
Rev Cardiovasc Med
; 15(1): 71-3, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-24762470
13.
Bortezomib, ascorbic acid and melphalan (BAM) therapy for patients with newly diagnosed multiple myeloma: an effective and well-tolerated frontline regimen.
Eur J Haematol
; 82(6): 433-9, 2009 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-19226361
14.
Zoledronic acid markedly improves bone mineral density for patients with monoclonal gammopathy of undetermined significance and bone loss.
Clin Cancer Res
; 14(19): 6289-95, 2008 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-18829511
15.
Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1/2 study after longer follow-up.
Ann Hematol
; 87(8): 623-31, 2008 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-18463870
16.
Durable Response to Carboplatin, Etoposide, Nivolumab, and Ipilimumab in Metastatic High-Grade Neuroendocrine Carcinoma of the Gallbladder.
Pancreas
; 49(2): e19-e20, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32049953